Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

658
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
658
Glaucoma: Overview01:25

Glaucoma: Overview

860
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
860
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

785
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
785

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Cerebral Basis for Visual Discomfort and Visual Stress.

Vision (Basel, Switzerland)·2026
Same author

Homonymous hemianopia in posterior cortical atrophy: right-left asymmetry, progression over time and relationship to the classical neuropsychological deficits.

Frontiers in neurology·2026
Same author

Comment: Clinical Characteristics and Treatment Effects of Chronic Immunotherapy in Idiopathic Recurrent Neuroretinitis and Idiopathic Recurrent Papillitis: Describing a Potential New Phenotype.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society·2025
Same author

Retinal nerve fibre layer thickness is associated with attention and predicts risk states of dementia.

Brain communications·2025
Same author

Unveiling the Riddoch phenomenon: a regression analysis of stroke-induced homonymous hemianopia.

Frontiers in neurology·2025
Same author

"Do You Hear What I Hear?" Speech and Voice Alterations in Hearing Loss: A Systematic Review.

Journal of clinical medicine·2025

Related Experiment Video

Updated: Sep 24, 2025

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

14.2K

Optic neuritis with potential for poor outcome.

Sarah A Cooper1, Sara Geraldine Leddy2, Nicholas Tom Skipper3

  • 1Neurology, University Hospitals Sussex NHS Foundation Trust, Brighton, UK sarah.cooper56@nhs.net.

Practical Neurology
|May 2, 2022
PubMed
Summary
This summary is machine-generated.

Early treatment for optic neuritis (ON) is crucial. Differentiating between multiple sclerosis-associated ON and autoimmune forms like MOG-ON and AQP4-ON guides timely intervention for better visual outcomes.

Keywords:
CLINICAL NEUROLOGYNEUROOPHTHALMOLOGYOPHTHALMOLOGY

More Related Videos

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.5K
Visual Evoked Potential Recording in a Rat Model of Experimental Optic Nerve Demyelination
06:49

Visual Evoked Potential Recording in a Rat Model of Experimental Optic Nerve Demyelination

Published on: July 29, 2015

12.4K

Related Experiment Videos

Last Updated: Sep 24, 2025

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

14.2K
Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.5K
Visual Evoked Potential Recording in a Rat Model of Experimental Optic Nerve Demyelination
06:49

Visual Evoked Potential Recording in a Rat Model of Experimental Optic Nerve Demyelination

Published on: July 29, 2015

12.4K

Area of Science:

  • Ophthalmology
  • Neurology
  • Immunology

Background:

  • Corticosteroids accelerate visual recovery in optic neuritis (ON) but do not improve long-term outcomes, particularly in multiple sclerosis (MS).
  • Non-MS forms of ON, including aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) associated optic neuritis, can mimic MS-ON but carry a risk of worse visual prognosis.
  • Clinical features and neuroimaging are key to differentiating these conditions.

Purpose of the Study:

  • To contrast the clinical presentations of MOG-ON and AQP4-ON with MS/idiopathic demyelinating ON (MS/IDON).
  • To provide an approach to acute management of ON while awaiting antibody test results.
  • To highlight the importance of early treatment in non-MS/IDON for visual outcomes.

Main Methods:

  • Review of clinical features and neuroimaging findings in different types of ON.
  • Comparison of diagnostic criteria for MS/IDON, MOG-ON, and AQP4-ON.
  • Discussion of treatment strategies, including corticosteroids and plasma exchange.

Main Results:

  • MOG-ON and AQP4-ON present similarly to MS/IDON but require distinct management approaches.
  • Early high-dose corticosteroid therapy significantly impacts visual outcomes in non-MS/IDON.
  • Prompt plasma exchange may be beneficial in severe cases of non-MS/IDON.

Conclusions:

  • Distinguishing between MS/IDON, MOG-ON, and AQP4-ON is critical for appropriate and timely treatment.
  • Early intervention with high-dose corticosteroids and potentially plasma exchange can preserve vision in non-MS/IDON.
  • Further research into the specific immunopathogenesis and treatment of MOG-ON and AQP4-ON is warranted.